Advertisement

Drug Safety

, Volume 31, Issue 6, pp 515–524 | Cite as

Adverse Drug Reaction Reporting by Patients in the Netherlands Three Years of Experience

  • Joyce de Langen
  • Florence van Hunsel
  • Anneke Passier
  • Lolkje de Jong-van den Berg
  • Kees van Grootheest
Original Research Article

Abstract

Background: There has been discussion about the acceptance of adverse drug reactions (ADRs) reported by patients to spontaneous reporting systems. Lack of experience with patient reporting in real life was one of the main drawbacks in this debate. This study covers 3 years of experience with patient reporting in daily practice. We compared patient reports with reports from healthcare professionals. Although patients have the opportunity to report ADRs in several countries, little is published in the literature about the contribution that patient reports have in practice. To our knowledge, this paper is the first to describe long-term experiences with patient reporting as part of a spontaneous reporting system.

Methods: The number of reports received, age and sex of the reporters, characteristics of the most frequently reported drugs and characteristics of the ADRs (most frequently reported ADRs, seriousness, outcome) in a 3-year period (April 2004–April 2007) were compared between patient reports and reports from healthcare professionals.

Findings: During this 3-year period, the Netherlands Pharmacovigilance Centre Lareb received 2522 reports directly from patients, concerning 5401 ADRs. In the same period, healthcare professionals submitted 10 635 reports, concerning 16 722 ADRs. Differences were found in the categories of seriousness and outcome of the reported ADRs between patients and healthcare professionals. Conversely, similarities between patient reports and reports from healthcare professionals were found in age, sex, most frequently reported ADRs and most frequently reported drugs.

Interpretation: Our study highlights clearly that valuable differences between ADR reports from patients and reports from healthcare professionals exist. Differences in interpretation by patients and healthcare professionals may cause the observed disparities in seriousness and outcome of reported ADRs. However, the similarities between patient reports and reports from healthcare professionals in most frequently reported ADRs and most frequently reported drugs are striking. After 3 years of experience with patient reporting, we conclude that patient reporting in spontaneous reporting systems is feasible and that it contributes significantly to a reliable pharmacovigilance.

Keywords

Healthcare Professional Octreotide Acromegaly Pathological Gambling Patient Report 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No funding was received for the conduct of this study or the preparation of this report.

The authors have no conflicts of interest that are directly relevant to the content of this manuscript. Joyce de Langen, Florence van Hunsel, Anneke Passier and Kees van Grootheest contributed to the design of the study, the analysis and interpretation of data, and writing and revising the manuscript. Lolkje de Jong-van den Berg critically reviewed the manuscript. Kees van Grootheest took overall responsibility for the study and the manuscript. All authors approved the final version of the manuscript.

References

  1. 1.
    Mitchell AS, Henry DA, Hennrikus D, et al. Adverse drug reactions: can consumers provide early warning? Pharmacoepidemiol Drug Saf 1994; 3: 257–64CrossRefGoogle Scholar
  2. 2.
    van Grootheest AC, van Puijenbroek EP, de Jong-van den Berg LTW. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11: 205–10PubMedCrossRefGoogle Scholar
  3. 3.
    Morrison-Griffiths S, Walley TJ, Park BK, et al. Reporting of adverse drug reactions by nurses. Lancet 2003; 361: 1347–8PubMedCrossRefGoogle Scholar
  4. 4.
    van Grootheest K, de Graaf L, de Jong-van den Berg LTW LTW. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26: 211–7PubMedCrossRefGoogle Scholar
  5. 5.
    BMA board of science. Reporting adverse drug reactions: a guide for healthcare professionals 2006 [online]. Available from URL: http://www.bma.org.uk/ap.nsf/content/AdverseDrugRe-actions [Accessed 2007 Sep 17]
  6. 6.
    Blenkinsopp A, Wilkie P, Wang M. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 2006; 63: 148–56CrossRefGoogle Scholar
  7. 7.
    van Grootheest AC, Passier JLM, van Puijenbroek EP. Direct reporting of side effects by the patient: favourable experience in the first year. Ned Tijdschr Geneesk 2005; 149: 529–33Google Scholar
  8. 8.
    Council for International Organizations of Medical Sciences. International reporting of adverse drug reactions. CIOMS working group report. Geneva: World Health Organisation, 1987Google Scholar
  9. 9.
    The ATC/DDD system 2007 [online]. Available from URL: http://www.whocc.no/atcddd/ [Accessed 2007 Sep 17]
  10. 10.
    Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109–17PubMedCrossRefGoogle Scholar
  11. 11.
    Brown EG. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Saf 2002; 25: 445–52PubMedCrossRefGoogle Scholar
  12. 12.
    van Grootheest K, de Jong-van den Berg L. Patients’ role in reporting adverse drug reactions. Expert Opin Drug Saf 2004; 3: 363–8PubMedCrossRefGoogle Scholar
  13. 13.
    De Bruin ML, van Puijenbroek EP, Bracke M, et al. Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data. Pharmacoepidemiol Drug Saf 2006 Feb; 15(2): 99–105PubMedCrossRefGoogle Scholar
  14. 14.
    de Jong-van den Berg LTW. Women and drug use. Pharm Weekbl 2001; 136: 1624–8Google Scholar
  15. 15.
    Medawar C, Herxheimer A, Bell A, et al. Paroxetine, panorama and user reporting of ADRs: consumer intelligence matters in clinical practice and post-marketing drug surveillance. Int J Risk Saf Med 2002; 13: 161–9Google Scholar
  16. 16.
    Golomb B, Evans M. Risk factors for rhabdomyolysis with simvastatin and atorvastatin. Drug Saf 2006; 29(12): 1191–2PubMedCrossRefGoogle Scholar
  17. 17.
    Passier JLM, Srivastava N, van Puijenbroek EP. Isotretinoin-induced inflammatory bowel disease. Neth J Med 2006; 64(2): 52–4PubMedGoogle Scholar
  18. 18.
    Passier JLM. Lithium and hyperparathyroidism. Geneesmid-delenbulletin 2005; 39(11): 131–2Google Scholar
  19. 19.
    van Grootheest AC, de Graaf L. Pergolide en gokverslaving. Geneesmiddelenbulletin 2006; 40(8): 86–7Google Scholar
  20. 20.
    Dutch SPC. Permax® [online]. Available from URL: http://www.cbg-meb.nl/IB-teksten/h14587-h14588-h14589.pdf [Accessed 2000 Jan 2]
  21. 21.
    Dutch SPC. Sandostatin® [online]. Available from URL: http://www.cbg-meb.nl/IB-teksten/h12612-h12613-h12614-h1499-7.pdf [Accessed 2007 Oct 25]
  22. 22.
    US SPC. Sandostatin® [online]. Available from URL: http://www.fda.gov/cder/foi/label/2005/019667s050lbl.pdf [Accessed 2007 Oct 25]
  23. 23.
    May A, Lederbogen S, Diener HC. Octreotide dependency and headache: a case report. Cephalalgia 1994; 14(4): 303–4PubMedCrossRefGoogle Scholar
  24. 24.
    Donangelo I, Rodacki M, Peixoto MC, et al. Dependency and analgesia related to treatment with subcutaneous octreotide in patients with growth hormone-secreting tumors. Endocr Pract 2004; 10(2): 107–11PubMedGoogle Scholar
  25. 25.
    Levy MJ, Goadsby PJ. Octreotide dependency: a cautionary tale [abstract]. Endocrine Abstracts 2004; 7: 110Google Scholar
  26. 26.
    Levy MJ, Matharu MS, Meeran K, et al. The clinical characteristics of headache in patients with pituitary tumours. Brain 2005; 128 (Pt 8): 1921–30PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Joyce de Langen
    • 1
  • Florence van Hunsel
    • 1
  • Anneke Passier
    • 1
  • Lolkje de Jong-van den Berg
    • 2
  • Kees van Grootheest
    • 1
    • 2
  1. 1.Netherlands Pharmacovigilance Centre Lareb’s-HertogenboschMH’s-Hertogenboschthe Netherlands
  2. 2.Department of PharmacyUniversity of GroningenGroningenthe Netherlands

Personalised recommendations